schliessen

Filtern

 

Bibliotheken

Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)

ᅟ FDG PET/CT ( 18 F-fluoro-deoxy-glucose positron emission tomography/computed tomography) is a useful tool to image multiple myeloma (MM). However, simple and reproducible reporting criteria are still lacking and there is the need for harmonization. Recently, a group of Italian nuclear medicine exp... Full description

Journal Title: European journal of nuclear medicine and molecular imaging 2017, Vol.45 (5), p.712-719
Main Author: Nanni, Cristina
Other Authors: Versari, Annibale , Chauvie, Stephane , Bertone, Elisa , Bianchi, Andrea , Rensi, Marco , Bellò, Marilena , Gallamini, Andrea , Patriarca, Francesca , Gay, Francesca , Gamberi, Barbara , Ghedini, Pietro , Cavo, Michele , Fanti, Stefano , Zamagni, Elena
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Berlin/Heidelberg: Springer Berlin Heidelberg
ID: ISSN: 1619-7070
Link: https://www.ncbi.nlm.nih.gov/pubmed/29270787
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1979967696
title: Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)
format: Article
creator:
  • Nanni, Cristina
  • Versari, Annibale
  • Chauvie, Stephane
  • Bertone, Elisa
  • Bianchi, Andrea
  • Rensi, Marco
  • Bellò, Marilena
  • Gallamini, Andrea
  • Patriarca, Francesca
  • Gay, Francesca
  • Gamberi, Barbara
  • Ghedini, Pietro
  • Cavo, Michele
  • Fanti, Stefano
  • Zamagni, Elena
subjects:
  • Adult
  • Aged
  • Analysis
  • ardization
  • Bone marrow
  • Cardiology
  • Computed tomography
  • Criteria
  • Cytogenetics
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Imaging
  • IMPeTUs
  • Interpretation criteria
  • Italy
  • Lesions
  • Male
  • Medicine
  • Medicine & Public Health
  • Middle Aged
  • Multiple myeloma
  • Multiple Myeloma - diagnostic imaging
  • Nuclear Medicine
  • Oncology
  • Original Article
  • Orthopedics
  • Patients
  • Positron emission
  • Positron emission tomography
  • Positron Emission Tomography Computed Tomography
  • Prospective Studies
  • Radiology
  • Radiopharmaceuticals
  • Reproducibility
  • Reproducibility of Results
  • Tomography
  • Tomography, X-Ray Computed
ispartof: European journal of nuclear medicine and molecular imaging, 2017, Vol.45 (5), p.712-719
description: ᅟ FDG PET/CT ( 18 F-fluoro-deoxy-glucose positron emission tomography/computed tomography) is a useful tool to image multiple myeloma (MM). However, simple and reproducible reporting criteria are still lacking and there is the need for harmonization. Recently, a group of Italian nuclear medicine experts defined new visual descriptive criteria (Italian Myeloma criteria for Pet Use: IMPeTUs) to standardize FDG PET/CT evaluation in MM patients. The aim of this study was to assess IMPeTUs reproducibility on a large prospective cohort of MM patients. Materials and methods Patients affected by symptomatic MM who had performed an FDG PET/CT at baseline (PET0), after induction (PET-AI), and the end of treatment (PET-EoT) were prospectively enrolled in a multicenter trial (EMN02)(NCT01910987; MMY3033). After anonymization, PET images were uploaded in the web platform WIDEN® and hence distributed to five expert nuclear medicine reviewers for a blinded independent central review according to the IMPeTUs criteria. Consensus among reviewers was measured by the percentage of agreement and the Krippendorff’s alpha. Furthermore, on a patient-based analysis, the concordance among all the reviewers in terms of positivity or negativity of the FDG PET/CT scan was tested for different thresholds of positivity (Deauville score (DS 2, 3, 4, 5) for the main parameters (bone marrow, focal score, extra-medullary disease). Results Eighty-six patients (211 FDG PET/CT scans) were included in this analysis. Median patient age was 58 years (range, 35–66 years), 45% were male, 15% of them were in stage ISS (International Staging System) III, and 42% had high-risk cytogenetics. The percentage agreement was superior to 75% for all the time points, reaching 100% of agreement in assessing the presence skull lesions after therapy. Comparable results were obtained when the agreement analysis was performed using the Krippendorff’s alpha coefficient, either in every single time point of scanning (PET0, PET-AI or PET-EoT) or overall for all the scans together. DS proved highly reproducible with the highest reproducibility for score 4. Conclusions IMPeTUs criteria proved highly reproducible and could therefore be considered as a base for harmonizing PET interpretation in multiple myeloma. A prospective clinical validation of IMPeTUs criteria is underway.
language: eng
source:
identifier: ISSN: 1619-7070
fulltext: no_fulltext
issn:
  • 1619-7070
  • 1619-7089
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6961997
LOCALfalse
PrimoNMBib
record
control
sourceidgale_opena
recordidTN_cdi_proquest_miscellaneous_1979967696
sourceformatXML
sourcesystemPC
galeidA531989829
sourcerecordidA531989829
originalsourceidFETCH-LOGICAL-c496t-e292d21c7a5d0b974fc0407573e52e32d63cdd9efdd3f05f854aa1fa761fdab00
addsrcrecordideNp9kk9v0zAYhyMEYmPwAbggS1y2QzrbSfyH21S2UWmISbRny7VfT54Su9jpYed9cVylFDYBysGJ_fwevbF-VfWe4BnBmJ9njGkna0x43Ugsa_GiOiaMyJpjIV8e3jk-qt7kfI8xEVTI19URlbRsC35cPS7CCGmTYNSjjwGZ5Mu318jFhK4-X6Pby-X5fIl8QMO2H_2mBzQ8QB8HjU4XX29hucpnn5DzQfcoQS5MnqH9QSFG3XsdDpEn-qJGq-9w9rZ65XSf4d1-PalWV5fL-Zf65tv1Yn5xU5tWsrGGMrWlxHDdWbyWvHUGt5h3vIGOQkMta4y1Epy1jcOdE12rNXGaM-KsXmN8Ui0mb9xA0D6B2iQ_6PSgovbKBhhVtKrFslUgixyY66hmZE06I6gG6IASJrRY0-I6nVybFH9sIY9q8NlA3-sAcZsVkVxKxplkBf34DL2P21Tua0-1QjD6m7rTPSgfXByTNjupuugaIoUUVBZq9heqPBYGb2IA58v-kwCZAibFnBO4wz8TrHYlUlOJVCmR2pVIiZL5sB94ux7AHhK_WlMA_kxq_NSfMo3v_6umUzIXabiD9Mdd_DP0E3EM38w
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1979948862
display
typearticle
titleInterpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)
creatorNanni, Cristina ; Versari, Annibale ; Chauvie, Stephane ; Bertone, Elisa ; Bianchi, Andrea ; Rensi, Marco ; Bellò, Marilena ; Gallamini, Andrea ; Patriarca, Francesca ; Gay, Francesca ; Gamberi, Barbara ; Ghedini, Pietro ; Cavo, Michele ; Fanti, Stefano ; Zamagni, Elena
creatorcontribNanni, Cristina ; Versari, Annibale ; Chauvie, Stephane ; Bertone, Elisa ; Bianchi, Andrea ; Rensi, Marco ; Bellò, Marilena ; Gallamini, Andrea ; Patriarca, Francesca ; Gay, Francesca ; Gamberi, Barbara ; Ghedini, Pietro ; Cavo, Michele ; Fanti, Stefano ; Zamagni, Elena
descriptionᅟ FDG PET/CT ( 18 F-fluoro-deoxy-glucose positron emission tomography/computed tomography) is a useful tool to image multiple myeloma (MM). However, simple and reproducible reporting criteria are still lacking and there is the need for harmonization. Recently, a group of Italian nuclear medicine experts defined new visual descriptive criteria (Italian Myeloma criteria for Pet Use: IMPeTUs) to standardize FDG PET/CT evaluation in MM patients. The aim of this study was to assess IMPeTUs reproducibility on a large prospective cohort of MM patients. Materials and methods Patients affected by symptomatic MM who had performed an FDG PET/CT at baseline (PET0), after induction (PET-AI), and the end of treatment (PET-EoT) were prospectively enrolled in a multicenter trial (EMN02)(NCT01910987; MMY3033). After anonymization, PET images were uploaded in the web platform WIDEN® and hence distributed to five expert nuclear medicine reviewers for a blinded independent central review according to the IMPeTUs criteria. Consensus among reviewers was measured by the percentage of agreement and the Krippendorff’s alpha. Furthermore, on a patient-based analysis, the concordance among all the reviewers in terms of positivity or negativity of the FDG PET/CT scan was tested for different thresholds of positivity (Deauville score (DS 2, 3, 4, 5) for the main parameters (bone marrow, focal score, extra-medullary disease). Results Eighty-six patients (211 FDG PET/CT scans) were included in this analysis. Median patient age was 58 years (range, 35–66 years), 45% were male, 15% of them were in stage ISS (International Staging System) III, and 42% had high-risk cytogenetics. The percentage agreement was superior to 75% for all the time points, reaching 100% of agreement in assessing the presence skull lesions after therapy. Comparable results were obtained when the agreement analysis was performed using the Krippendorff’s alpha coefficient, either in every single time point of scanning (PET0, PET-AI or PET-EoT) or overall for all the scans together. DS proved highly reproducible with the highest reproducibility for score 4. Conclusions IMPeTUs criteria proved highly reproducible and could therefore be considered as a base for harmonizing PET interpretation in multiple myeloma. A prospective clinical validation of IMPeTUs criteria is underway.
identifier
0ISSN: 1619-7070
1EISSN: 1619-7089
2DOI: 10.1007/s00259-017-3909-8
3PMID: 29270787
languageeng
publisherBerlin/Heidelberg: Springer Berlin Heidelberg
subjectAdult ; Aged ; Analysis ; ardization ; Bone marrow ; Cardiology ; Computed tomography ; Criteria ; Cytogenetics ; Female ; Fluorodeoxyglucose F18 ; Humans ; Imaging ; IMPeTUs ; Interpretation criteria ; Italy ; Lesions ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - diagnostic imaging ; Nuclear Medicine ; Oncology ; Original Article ; Orthopedics ; Patients ; Positron emission ; Positron emission tomography ; Positron Emission Tomography Computed Tomography ; Prospective Studies ; Radiology ; Radiopharmaceuticals ; Reproducibility ; Reproducibility of Results ; Tomography ; Tomography, X-Ray Computed
ispartofEuropean journal of nuclear medicine and molecular imaging, 2017, Vol.45 (5), p.712-719
rights
0Springer-Verlag GmbH Germany, part of Springer Nature 2017
1COPYRIGHT 2018 Springer
2European Journal of Nuclear Medicine and Molecular Imaging is a copyright of Springer, (2017). All Rights Reserved.
lds50peer_reviewed
citedbyFETCH-LOGICAL-c496t-e292d21c7a5d0b974fc0407573e52e32d63cdd9efdd3f05f854aa1fa761fdab00
citesFETCH-LOGICAL-c496t-e292d21c7a5d0b974fc0407573e52e32d63cdd9efdd3f05f854aa1fa761fdab00
orcidid0000-0003-2000-1599
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29270787$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Nanni, Cristina
1Versari, Annibale
2Chauvie, Stephane
3Bertone, Elisa
4Bianchi, Andrea
5Rensi, Marco
6Bellò, Marilena
7Gallamini, Andrea
8Patriarca, Francesca
9Gay, Francesca
10Gamberi, Barbara
11Ghedini, Pietro
12Cavo, Michele
13Fanti, Stefano
14Zamagni, Elena
title
0Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)
1European journal of nuclear medicine and molecular imaging
addtitle
0Eur J Nucl Med Mol Imaging
1Eur J Nucl Med Mol Imaging
descriptionᅟ FDG PET/CT ( 18 F-fluoro-deoxy-glucose positron emission tomography/computed tomography) is a useful tool to image multiple myeloma (MM). However, simple and reproducible reporting criteria are still lacking and there is the need for harmonization. Recently, a group of Italian nuclear medicine experts defined new visual descriptive criteria (Italian Myeloma criteria for Pet Use: IMPeTUs) to standardize FDG PET/CT evaluation in MM patients. The aim of this study was to assess IMPeTUs reproducibility on a large prospective cohort of MM patients. Materials and methods Patients affected by symptomatic MM who had performed an FDG PET/CT at baseline (PET0), after induction (PET-AI), and the end of treatment (PET-EoT) were prospectively enrolled in a multicenter trial (EMN02)(NCT01910987; MMY3033). After anonymization, PET images were uploaded in the web platform WIDEN® and hence distributed to five expert nuclear medicine reviewers for a blinded independent central review according to the IMPeTUs criteria. Consensus among reviewers was measured by the percentage of agreement and the Krippendorff’s alpha. Furthermore, on a patient-based analysis, the concordance among all the reviewers in terms of positivity or negativity of the FDG PET/CT scan was tested for different thresholds of positivity (Deauville score (DS 2, 3, 4, 5) for the main parameters (bone marrow, focal score, extra-medullary disease). Results Eighty-six patients (211 FDG PET/CT scans) were included in this analysis. Median patient age was 58 years (range, 35–66 years), 45% were male, 15% of them were in stage ISS (International Staging System) III, and 42% had high-risk cytogenetics. The percentage agreement was superior to 75% for all the time points, reaching 100% of agreement in assessing the presence skull lesions after therapy. Comparable results were obtained when the agreement analysis was performed using the Krippendorff’s alpha coefficient, either in every single time point of scanning (PET0, PET-AI or PET-EoT) or overall for all the scans together. DS proved highly reproducible with the highest reproducibility for score 4. Conclusions IMPeTUs criteria proved highly reproducible and could therefore be considered as a base for harmonizing PET interpretation in multiple myeloma. A prospective clinical validation of IMPeTUs criteria is underway.
subject
0Adult
1Aged
2Analysis
3ardization
4Bone marrow
5Cardiology
6Computed tomography
7Criteria
8Cytogenetics
9Female
10Fluorodeoxyglucose F18
11Humans
12Imaging
13IMPeTUs
14Interpretation criteria
15Italy
16Lesions
17Male
18Medicine
19Medicine & Public Health
20Middle Aged
21Multiple myeloma
22Multiple Myeloma - diagnostic imaging
23Nuclear Medicine
24Oncology
25Original Article
26Orthopedics
27Patients
28Positron emission
29Positron emission tomography
30Positron Emission Tomography Computed Tomography
31Prospective Studies
32Radiology
33Radiopharmaceuticals
34Reproducibility
35Reproducibility of Results
36Tomography
37Tomography, X-Ray Computed
issn
01619-7070
11619-7089
fulltextfalse
rsrctypearticle
creationdate2017
recordtypearticle
recordideNp9kk9v0zAYhyMEYmPwAbggS1y2QzrbSfyH21S2UWmISbRny7VfT54Su9jpYed9cVylFDYBysGJ_fwevbF-VfWe4BnBmJ9njGkna0x43Ugsa_GiOiaMyJpjIV8e3jk-qt7kfI8xEVTI19URlbRsC35cPS7CCGmTYNSjjwGZ5Mu318jFhK4-X6Pby-X5fIl8QMO2H_2mBzQ8QB8HjU4XX29hucpnn5DzQfcoQS5MnqH9QSFG3XsdDpEn-qJGq-9w9rZ65XSf4d1-PalWV5fL-Zf65tv1Yn5xU5tWsrGGMrWlxHDdWbyWvHUGt5h3vIGOQkMta4y1Epy1jcOdE12rNXGaM-KsXmN8Ui0mb9xA0D6B2iQ_6PSgovbKBhhVtKrFslUgixyY66hmZE06I6gG6IASJrRY0-I6nVybFH9sIY9q8NlA3-sAcZsVkVxKxplkBf34DL2P21Tua0-1QjD6m7rTPSgfXByTNjupuugaIoUUVBZq9heqPBYGb2IA58v-kwCZAibFnBO4wz8TrHYlUlOJVCmR2pVIiZL5sB94ux7AHhK_WlMA_kxq_NSfMo3v_6umUzIXabiD9Mdd_DP0E3EM38w
startdate20171221
enddate20171221
creator
0Nanni, Cristina
1Versari, Annibale
2Chauvie, Stephane
3Bertone, Elisa
4Bianchi, Andrea
5Rensi, Marco
6Bellò, Marilena
7Gallamini, Andrea
8Patriarca, Francesca
9Gay, Francesca
10Gamberi, Barbara
11Ghedini, Pietro
12Cavo, Michele
13Fanti, Stefano
14Zamagni, Elena
general
0Springer Berlin Heidelberg
1Springer
2Springer Nature B.V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
93V.
107RV
117TK
127X7
137XB
1488E
158AO
168FE
178FG
188FH
198FI
208FJ
218FK
22ABUWG
23ARAPS
24AZQEC
25BBNVY
26BENPR
27BGLVJ
28BHPHI
29DWQXO
30FYUFA
31GHDGH
32GNUQQ
33HCIFZ
34K9.
35KB0
36LK8
37M0S
38M1P
39M7P
40NAPCQ
41P5Z
42P62
43PQEST
44PQQKQ
45PQUKI
46PRINS
477X8
48CLFQK
orcididhttps://orcid.org/0000-0003-2000-1599
sort
creationdate20171221
titleInterpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)
authorNanni, Cristina ; Versari, Annibale ; Chauvie, Stephane ; Bertone, Elisa ; Bianchi, Andrea ; Rensi, Marco ; Bellò, Marilena ; Gallamini, Andrea ; Patriarca, Francesca ; Gay, Francesca ; Gamberi, Barbara ; Ghedini, Pietro ; Cavo, Michele ; Fanti, Stefano ; Zamagni, Elena
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c496t-e292d21c7a5d0b974fc0407573e52e32d63cdd9efdd3f05f854aa1fa761fdab00
rsrctypearticles
prefilterarticles
languageeng
creationdate2017
topic
0Adult
1Aged
2Analysis
3ardization
4Bone marrow
5Cardiology
6Computed tomography
7Criteria
8Cytogenetics
9Female
10Fluorodeoxyglucose F18
11Humans
12Imaging
13IMPeTUs
14Interpretation criteria
15Italy
16Lesions
17Male
18Medicine
19Medicine & Public Health
20Middle Aged
21Multiple myeloma
22Multiple Myeloma - diagnostic imaging
23Nuclear Medicine
24Oncology
25Original Article
26Orthopedics
27Patients
28Positron emission
29Positron emission tomography
30Positron Emission Tomography Computed Tomography
31Prospective Studies
32Radiology
33Radiopharmaceuticals
34Reproducibility
35Reproducibility of Results
36Tomography
37Tomography, X-Ray Computed
toplevelpeer_reviewed
creatorcontrib
0Nanni, Cristina
1Versari, Annibale
2Chauvie, Stephane
3Bertone, Elisa
4Bianchi, Andrea
5Rensi, Marco
6Bellò, Marilena
7Gallamini, Andrea
8Patriarca, Francesca
9Gay, Francesca
10Gamberi, Barbara
11Ghedini, Pietro
12Cavo, Michele
13Fanti, Stefano
14Zamagni, Elena
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8ProQuest Central (Corporate)
9Nursing & Allied Health Database
10Neurosciences Abstracts
11Health & Medical Collection
12ProQuest Central (purchase pre-March 2016)
13Medical Database (Alumni Edition)
14ProQuest Pharma Collection
15ProQuest SciTech Collection
16ProQuest Technology Collection
17ProQuest Natural Science Collection
18Hospital Premium Collection
19Hospital Premium Collection (Alumni Edition)
20ProQuest Central (Alumni) (purchase pre-March 2016)
21ProQuest Central (Alumni Edition)
22Advanced Technologies & Aerospace Collection
23ProQuest Central Essentials
24Biological Science Collection
25ProQuest Central
26Technology Collection
27Natural Science Collection
28ProQuest Central Korea
29Health Research Premium Collection
30Health Research Premium Collection (Alumni)
31ProQuest Central Student
32SciTech Premium Collection
33ProQuest Health & Medical Complete (Alumni)
34Nursing & Allied Health Database (Alumni Edition)
35ProQuest Biological Science Collection
36Health & Medical Collection (Alumni Edition)
37Medical Database
38Biological Science Database
39Nursing & Allied Health Premium
40Advanced Technologies & Aerospace Database
41ProQuest Advanced Technologies & Aerospace Collection
42ProQuest One Academic Eastern Edition
43ProQuest One Academic
44ProQuest One Academic UKI Edition
45ProQuest Central China
46MEDLINE - Academic
47OpenAIRE
jtitleEuropean journal of nuclear medicine and molecular imaging
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Nanni, Cristina
1Versari, Annibale
2Chauvie, Stephane
3Bertone, Elisa
4Bianchi, Andrea
5Rensi, Marco
6Bellò, Marilena
7Gallamini, Andrea
8Patriarca, Francesca
9Gay, Francesca
10Gamberi, Barbara
11Ghedini, Pietro
12Cavo, Michele
13Fanti, Stefano
14Zamagni, Elena
formatjournal
genrearticle
ristypeJOUR
atitleInterpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)
jtitleEuropean journal of nuclear medicine and molecular imaging
stitleEur J Nucl Med Mol Imaging
addtitleEur J Nucl Med Mol Imaging
date2017-12-21
risdate2017
volume45
issue5
spage712
epage719
pages712-719
issn1619-7070
eissn1619-7089
abstractᅟ FDG PET/CT ( 18 F-fluoro-deoxy-glucose positron emission tomography/computed tomography) is a useful tool to image multiple myeloma (MM). However, simple and reproducible reporting criteria are still lacking and there is the need for harmonization. Recently, a group of Italian nuclear medicine experts defined new visual descriptive criteria (Italian Myeloma criteria for Pet Use: IMPeTUs) to standardize FDG PET/CT evaluation in MM patients. The aim of this study was to assess IMPeTUs reproducibility on a large prospective cohort of MM patients. Materials and methods Patients affected by symptomatic MM who had performed an FDG PET/CT at baseline (PET0), after induction (PET-AI), and the end of treatment (PET-EoT) were prospectively enrolled in a multicenter trial (EMN02)(NCT01910987; MMY3033). After anonymization, PET images were uploaded in the web platform WIDEN® and hence distributed to five expert nuclear medicine reviewers for a blinded independent central review according to the IMPeTUs criteria. Consensus among reviewers was measured by the percentage of agreement and the Krippendorff’s alpha. Furthermore, on a patient-based analysis, the concordance among all the reviewers in terms of positivity or negativity of the FDG PET/CT scan was tested for different thresholds of positivity (Deauville score (DS 2, 3, 4, 5) for the main parameters (bone marrow, focal score, extra-medullary disease). Results Eighty-six patients (211 FDG PET/CT scans) were included in this analysis. Median patient age was 58 years (range, 35–66 years), 45% were male, 15% of them were in stage ISS (International Staging System) III, and 42% had high-risk cytogenetics. The percentage agreement was superior to 75% for all the time points, reaching 100% of agreement in assessing the presence skull lesions after therapy. Comparable results were obtained when the agreement analysis was performed using the Krippendorff’s alpha coefficient, either in every single time point of scanning (PET0, PET-AI or PET-EoT) or overall for all the scans together. DS proved highly reproducible with the highest reproducibility for score 4. Conclusions IMPeTUs criteria proved highly reproducible and could therefore be considered as a base for harmonizing PET interpretation in multiple myeloma. A prospective clinical validation of IMPeTUs criteria is underway.
copBerlin/Heidelberg
pubSpringer Berlin Heidelberg
pmid29270787
doi10.1007/s00259-017-3909-8
orcididhttps://orcid.org/0000-0003-2000-1599